Pfizer Targets $61B 2026 Revenue Floor, Adds Metsera Obesity Assets for $10B
Pfizer trades at an 8.6x forward P/E with a 6.9% dividend yield and has set a $61B revenue floor for 2026 after activist Starboard Value’s exit. The company spent $10B to acquire Metsera’s injectable obesity assets, licensed a GLP-1 candidate from YaoPharma and plans 15 programs with $10.5–11.5B in R&D.
1. Near-Term Earnings Headwinds Intensify
Pfizer enters 2026 under significant earnings pressure following a steep decline in COVID-19 product revenue and the dilutive impact of recent acquisitions. Management forecasts that legacy vaccine and antiviral sales will contract by more than $20 billion year-over-year, representing nearly one-third of total corporate revenue in 2025. At the same time, the $43 billion Seagen deal and the $10 billion Metsera acquisition are expected to introduce roughly $3 billion of non-GAAP dilution to per-share earnings this year, driven largely by amortization and financing costs.
2. Metsera Deal Strengthens Obesity Pipeline
In November 2025, Pfizer closed its $10 billion purchase of Metsera, securing exclusive rights to two late-stage obesity assets: MET-097i, an injectable GLP-1 candidate designed for monthly dosing, and MET-107, an oral small-molecule GLP-1. Phase III data released last month show that MET-097i patients achieved an average weight loss of 18.2% at 48 weeks, outperforming the current market leader’s 14.8% outcome. Analysts now project obesity franchise sales of $6 billion by 2030, up from prior estimates of $3.5 billion.
3. Elevated R&D Investment Fuels Mid-Term Growth
Pfizer plans to advance approximately 15 new clinical programs in 2026, allocating $10.5–$11.5 billion to research and development—up nearly 15% from last year. Key priorities include 60 oncology candidates acquired via Seagen, with anticipated data readouts for three ADC therapies by Q3. In addition, a recently licensed bispecific antibody targeting solid tumors could enter Phase II trials this year, potentially adding $1.2 billion of peak annual sales if approved.
4. Stabilized Balance Sheet and Shareholder Returns
Despite short-term headwinds, Pfizer maintains a strong financial foundation, targeting a conservative revenue floor of $61 billion for 2026. The company ended Q4 with $16 billion in cash and equivalents against $35 billion of debt maturing beyond 2028. A $4 billion cost-savings program is on track to deliver $2 billion of annual efficiencies by mid-2026, underpinning the company’s nearly 7% dividend yield. Free cash flow is expected to exceed $15 billion, supporting both ongoing R&D and uninterrupted shareholder distributions.